Remove 2029 Remove Licensing Remove Pharmaceuticals
article thumbnail

CMS Finalizes Guidance on Medicare Part D Manufacturer Discount Program

FDA Law Blog: Biosimilars

state pharmaceutical assistance programs). Each phase-in policy allows eligible manufacturers to build up in a stepwise manner to the 10% and 20% applicable discounts by 2029 and 2031, respectively. After 2024, the PDP sponsors will pay the enrollees’ 5% coinsurance during the catastrophic phase.

article thumbnail

Making a “Miracle” HIV Medicine

Codon

million new HIV infections by 2029, undermining progress toward the UN’s goal. In 2024, the pharmaceutical company Gilead announced that a single injection of lenacapavir protected 96 to 100 percent of recipients from HIV for up to six months. By 1987, the FDA licensed zidovudine after trials showed it increased survival rates.